natgillin/translations-raw huggingface dataset:
Det repoduktive system Ikke almindelig:
Reproductive system and breast disorders
Forhøjede leverenzymer Hyperbilirubinæmi, hepatitis, gulsot Leversvigt9, levernekrose og mammae Gynæcomasti, erektil dysfunktion, menorrhagi, uregelmæssig menstruation, seksuel dysfunktion, smerter i brystvorterne, brystforstørrelse, scrotalt ødem
Gynaecomastia, erectile dysfunction, menorrhagia, menstruation irregular, sexual dysfunction, nipple pain, breast enlargement, scrotal oedema
Søvnmangel Depression, nedsat libido, angst Konfusion
Insomnia Depression, libido decreased, anxiety Confusional state
1 På patientårsbasis blev kardielle hændelser, herunder hjertesvigt, observeret oftere hos patienter med transformeret CML i forhold til patienter med kronisk CML.
1 On a patient-year basis, cardiac events including congestive heart failure were more commonly observed in patients with transformed CML than in patients with chronic CML.
2 Hovedpine var mest almindeligt hos GIST- patienter.
2 Headache was the most common in GIST patients.
3 Pleuralt ekssudat blev oftere observeret hos patienter med GIST og hos patienter med transformeret CML (CML- AP og CML- BC) end hos patienter med kronisk CML.
3 Pleural effusion was reported more commonly in patients with GIST and in patients with transformed CML (CML-AP and CML-BC) than in patients with chronic CML.
4+5 Abdominalsmerter og gastrointestinal blødning blev oftest observeret hos patienter med GIST.
4+5 Abdominal pain and gastrointestinal haemorrhage were most commonly observed in GIST patients.
6 Muskuloskeletale smerter og relaterede hændelser blev oftere observeret hos patienter med CML end hos patienter med GIST.
6 Musculoskeletal pain and related events were more commonly observed in patients with CML than in GIST patients.
7 Pneumoni blev oftest observeret hos patienter med transformeret CML og hos patienter med GIST.
7 Pneumonia was reported most commonly in patients with transformed CML and in patients with GIST.
8 Rødmen var mest almindeligt host patienter med GIST og blødning (hæmatom og blødning) var mest almindeligt hos patienter med GIST og med transformeret CML (CML- AP og CML- BC).
8 Flushing was most common in GIST patients and bleeding (haematoma, haemorrhage) was most common in patients with GIST and with transformed CML (CML-AP and CML-BC).
9 Der er rapporteret tilfælde af fatalt leversvigt og levernekrose.
9 Some fatal cases of hepatic failure and of hepatic necrosis have been reported.
Følgende typer af reaktioner er hovedsageligt blevet rapporteret fra erfaring med Glivec efter markedsføring.
The following types of reactions have been reported mainly from post-marketing experience with Glivec.
Dette inkluderer spontane kasuistiker såvel som alvorlige bivirkninger fra igangværende studier, de udvidede adgangsprogrammer, kliniske farmakologistudier og forskningsstudier med ikke godkendte indikationer.
This includes spontaneous case reports as well as serious adverse events from ongoing studies, the expanded access programmes, clinical pharmacology studies and exploratory studies in unapproved indications.
Eftersom disse reaktioner er rapporteret fra en population af ukendt størrelse, er det ikke altid muligt at bestemme frekvensen pålideligt eller at fastlægge en kausal sammenhæng med eksponering med imatinib.
Because these reactions are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to imatinib exposure.
Bivirkninger fra erfaring med Glivec efter markedsføring
Adverse reactions from post-marketing reports
Benigne, maligne og uspecificerede tumorer (inkl. cyster og polypper) Ikke kendt:
Neoplasm benign, malignant and unspecified (including cysts and polyps) Not known:
Tumorblødning/ tumornekrose
Tumour haemorrhage/ tumour necrosis
Hjertesækbetændelse, hjertetamponade
Pericarditis, cardiac tamponade
Ikke kendt:
Nervous system disorders Not known:
Hjerneødem
Cerebral oedema
Glaslegemeblødning
Vitreous haemorrhage
Mave- tarmkanalen
Respiratory, thoracic and mediastinal disorders Not known:
Akut respirationssvigt1, interstitiel lungesygdom
Acute respiratory failure1, interstitial lung disease
Hud og subkutane væv
Gastrointestinal disorders Not known:
Ileus/ intestinal obstruktion, gastrointestinal perforation, diverticulitis
Ileus/ intestinal obstruction, gastrointestinal perforation, diverticulitis
Ikke kendt:
Skin and subcutaneous tissue disorders Not known:
Lichenoid keratosis, lichen planus Toxisk epidermal nekrolyse
Lichenoid keratosis, lichen planus Toxic epidermal necrolysis
Knogler, led, muskler og bindevæv Ikke kendt:
Musculoskeletal and connective tissue disorders Not known:
Avaskulær necrose/ hoftenekrose
Avascular necrosis/ hip necrosis
Thrombose/ embolisme
Thrombosis/ embolism
1 Der er blevet rapporteret fatale tilfælde hos patienter med fremskreden sygdom, alvorlige infektioner, alvorlig neutropeni og andre alvorlige samtidige kliniske lidelser.
1 Fatal cases have been reported in patients with advanced disease, severe infections, severe neutropenia and other serious concomitant conditions.
Hæmatologi Cytopeni hos CML- patienter, særligt neutropeni og thrombocytopeni, har været gennemgående fund i alle undersøgelser med tegn på større hyppighed ved doser ≥750 mg (fase I undersøgelse).
12 Laboratory test abnormalities Haematology In CML, cytopenias, particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at high doses ≥ 750 mg (phase I study).
Incidensen af cytopeni hang imidlertid også tydeligt sammen med sygdomsstadiet, idet hyppighed af 3. eller 4. grads neutropeni (ANC < 1, 0 x 109/ l) og thrombocytopeni (thrombocyttal < 50 x 109/ l) var 4– 6 gange højere ved blastkrise og accelereret fase (59– 64% og 44– 63% for henholdsvis neutropeni og
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC < 1.0 x 109/ l) and thrombocytopenias (platelet count < 50 x 109/ l) being between 4 and 6 times higher in blast crisis and accelerated phase (59– 64% and 44– 63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
Der sås 4. grads neutropeni (ANC < 0, 5 x 109/ l) og thrombopeni (thrombocyttal < 10 x 109/ l) hos henholdsvis 3, 6% og < 1% af patienterne med nydiagnosticeret CML i kronisk fase.
In newly diagnosed chronic phase CML grade 4 neutropenia (ANC < 0.5 x 109/ l) and thrombocytopenia (platelet count < 10 x 109/ l) were observed in 3.6% and < 1% of patients, respectively.
Den gennemsnitlige varighed af neutropeni - og thrombocytopeniepisoderne varierede sædvanligvis fra henholdsvis 2– 3 uger og 3– 4 uger.
The median duration of the neutropenic and thrombocytopenic episodes usually ranged from 2 to 3 weeks, and from 3 to 4 weeks, respectively.
De hyppigst observerede alvorlige bivirkninger hos børn med CML var grad 3 eller 4 cytopenier med neutropeni, thrombocytopeni og anæmi.
In paediatric CML patients the most frequent toxicities observed were grade 3 or 4 cytopenias involving neutropenia, thrombocytopenia and anaemia.
Hos GIST patienter rapporteredes anæmi grad 3 og 4 hos henholdsvis 5, 4% og 0, 7% af patienterne, hvilket kan hænge sammen med gastrointestinal eller intra- tumoral blødning, i hvert fald hos enkelte af patienterne.
In patients with GIST, grade 3 and 4 anaemia was reported in 5.4% and 0.7% of patients, respectively, and may have been related to gastrointestinal or intra-tumoural bleeding in at least some of these patients.
Grad 3 og 4 neutropeni sås hos henholdsvis 7, 5% og 2, 7% af patienterne og grad 3 thrombocytopeni hos 0, 7% af patienterne.
Grade 3 and 4 neutropenia was seen in 7.5% and 2.7% of patients, respectively, and grade 3 thrombocytopenia in 0.7% of patients.
Ingen patienter udviklede grad 4 thrombocytopeni.
No patient developed grade 4 thrombocytopenia.
Biokemi Svære stigninger i transaminaser (< 5%) eller bilirubin (< 1%) blev observeret hos CML- patienterne og blev sædvanligvis behandlet med dosisreduktion eller seponering (den gennemsnitlige varighed af disse episoder var ca.
Biochemistry Severe elevation of transaminases (< 5%) or bilirubin (< 1%) was seen in CML patients and was usually managed with dose reduction or interruption (the median duration of these episodes was approximately one week).
Færre end 1% af CML- patienterne fik seponeret behandlingen permanent på grund af abnormaliteter i levertal.
Treatment was discontinued permanently because of liver laboratory abnormalities in less than 1% of CML patients.
Der blev hos GIST patienter (studie B2222) observeret stigning i grad 3 eller 4 ALT (alaninaminotransferase) hos 6, 8% og stigning i grad 3 eller 4 AST (aspartat aminotransferase) hos 4, 8%.
In GIST patients (study B2222), 6.8% of grade 3 or 4 ALT (alanine aminotransferase) elevations and 4.8% of grade 3 or 4 AST (aspartate aminotransferase) elevations were observed.
Der har været tilfælde af cytolytisk og cholestatisk hepatitis samt leversvigt, i nogle tilfælde var udfaldet fatalt, inkluderende én patient, der fik højdosis paracetamol.
There have been cases of cytolytic and cholestatic hepatitis and hepatic failure; in some of them outcome was fatal, including one patient on high dose paracetamol.
Erfaring med doser over 800 mg er begrænset.
Experience with doses greater than 800 mg is limited.
Enkelte sager med overdosering af Glivec er blevet rapporteret.
Isolated cases of Glivec overdose have been reported.
En patient i myeloid blastkrise tog uforvarende Glivec 1. 200 mg i 6 dage og oplevede Grad 1 stigninger i se- creatinin, Grad 2 ascites og forhøjede levertransaminaseniveauer samt Grade 3 stigninger i bilirubin.
A patient with myeloid blast crisis inadvertently took Glivec 1,200 mg for 6 days and experienced Grade 1 elevations of serum creatinine, Grade 2 ascites and elevated liver transaminase levels, and Grade 3 elevations of bilirubin.
Behandlingen blev midlertidigt seponeres og der sås fuldstændig normalisering af alle abnormiteter inden for en uge.
Treatment was temporarily interrupted and there was complete reversal of all abnormalities within one week.
Behandlingen blev genoptaget ved en dosis på 400 mg uden, at problemerne recidiverede.
Treatment was resumed at a dose of 400 mg without recurrence of problems.
En anden patient udviklede svære muskelkramper efter at have taget 1. 600 mg Glivec daglig i 6 dage.
Another patient developed severe muscle cramps after taking Glivec 1,600 mg daily for six days.
Efter seponering af behandlingen opstod fuldstændig ophør af muskelkramper, behandlingen blev efterfølgende genoptaget.
Following interruption of treatment, complete resolution of muscle cramps occurred, treatment was subsequently resumed.
Protein- tyrosinkinasehæmmer, ATC- kode:
Pharmacotherapeutic group: protein-tyrosine kinase inhibitor, ATC code:
Imatinib er en protein- tyrosinkinasehæmmer, som potent hæmmer Bcr- Abl tyrosinkinasen in vitro, in vivo og på cellulært niveau.
Imatinib is a protein-tyrosine kinase inhibitor which potently inhibits the Bcr-Abl tyrosine kinase at the in vitro, cellular and in vivo levels.
Stoffet hæmmer selektivt proliferationen og inducerer apoptosis i Bcr - Abl- positive cellelinier såvel som i friske leukæmiceller fra Philadelphia- kromosompositiv (Ph+) CML og hos patienter med akut lymfoblastisk leukæmi (ALL).
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and acute lymphoblastic leukaemia (ALL) patients.
I dyremodeller, hvor der anvendes Bcr- Abl- positive tumorceller, har stoffet som enkeltstof in vivo
In vivo the compound shows anti-tumour activity as a single agent in animal models using Bcr-Abl positive tumour cells.
Imatinib hæmmer også receptortyrosinkinaserne for thrombocytafledte vækstfaktorer (PDGF), PDGF - R, og stamcellefaktorer (SCF), c- Kit, og hæmmer PDGF - og SCF- medierede cellulære signaler.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events.
In vitro hæmmer imatinib proliferationen og inducerer apoptose i GIST- tumorcellerne, som udtrykker kit- mutationen.
In vitro, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumour (GIST) cells, which express an activating kit mutation.
Vedvarende aktivering af PDGF receptoren eller Abl protein tyrosin kinase, der opstår på grund af en fusion med andre proteiner eller konstitutiv produktion af PDGF er blevet impliceret i patogenesen af MDS/ MPD, HES/ CEL og DFSP.
Constitutive activation of the PDGF receptor or the Abl protein tyrosine kinases as a consequence of fusion to diverse partner proteins or constitutive production of PDGF have been implicated in the pathogenesis of MDS/ MPD, HES/ CEL and DFSP.
Imatinib hæmmer signalleringen og vækst af celler, der drives af dysreguleret PDGFR og Abl kinase aktivitet.
Imatinib inhibits signalling and proliferation of cells driven by dysregulated PDGFR and Abl kinase activity.
Kliniske undersøgelser vedrørende kronisk myeloid leukæmi Glivecs effekt er baseret på generelle hæmatologiske og cytogene responsrater og progressionsfri overlevelse.
Clinical studies in chronic myeloid leukaemia The effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival.
Der er ingen kontrollerede undersøgelser, undtagen hos nyligt diagnosticerede kronisk fase CML- patienter, der har vist klinisk bedring såsom forbedring af sygdomsrelaterede symptomer eller øget overlevelse.
Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.
Der er udført 3 store, internationale, åbne, ikke- kontrollerede fase II undersøgelser med patienter med Philadelphia- kromosompositiv (Ph+) CML i fremskreden blastkrise eller accelereret fase, andre Ph+ - leukæmier eller med CML i kronisk fase men tidligere behandlet med alfa- interferonbehandling (IFN) uden effekt.
Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive (Ph+) CML in advanced, blast or accelerated phase disease, other Ph+ leukaemias or with CML in the chronic phase but failing prior interferon-alpha (IFN) therapy.
I de kliniske undersøgelser var 38– 40% af patienterne ≥60 år, og 10– 12% af patienterne var ≥70 år.
In all clinical studies 38– 40% of patients were ≥ 60 years of age and 10– 12% of patients were ≥ 70 years of age.
Kronisk fase, nydiagnosticeret:
Chronic phase, newly diagnosed:
Denne fase III undersøgelse hos voksne patienter sammenlignede enkeltstof- behandling med Glivec med behandling med en kombination af interferon- alfa (IFN) og cytarabin (Ara- C).
This phase III study in adult patients compared treatment with either single-agent Glivec or a combination of interferon-alpha (IFN) plus cytarabine (Ara-C).
Patienter der ikke viste respons (manglende fuldstændig hæmatologisk respons (CHR) efter 6 måneder, øget leukocyttal, intet større cytogenetisk respons (MCyR) efter 24 måneder), tab af respons (tab af CHR eller MCyR) eller svær intolerance over for behandling, fik lov at krydse over til den anden behandlingsarm.
Patients showing lack of response (lack of complete haematological response (CHR) at 6 months, increasing WBC, no major cytogenetic response (MCyR) at 24 months), loss of response (loss of CHR or MCyR) or severe intolerance to treatment were allowed to cross over to the alternative treatment arm.
I Glivec- armen blev patienterne behandlet med 400 mg daglig.
In the Glivec arm, patients were treated with 400 mg daily.
I IFN- armen blev patienterne behandlet med en måldosis IFN på 5 MIE/ m2/ dag subkutant i kombination med subkutant Ara- C 20 mg/ m2/ dag i 10 dage/ måned.
In the IFN arm, patients were treated with a target dose of IFN of 5 MIU/ m2/ day subcutaneously in combination with subcutaneous Ara-C 20 mg/ m2/ day for 10 days/ month.
Ialt randomiseredes 1. 106 patienter, 553 til hver arm.
A total of 1,106 patients were randomised, 553 to each arm.
Gennemsnitsalderen var 51 år (range 18– 70 år), med 21, 9% patienter ≥60 år.
Median age was 51 years (range 18– 70 years), with 21.9% of patients ≥ 60 years of age.
59% var mænd, 41% kvinder; 89, 9% var af kaukatisk afstamning og 4, 7% af negroid afstamning.
There were 59% males and 41% females; 89.9% caucasian and 4.7% black patients.
Medianvarigheden af førstevalgsbehandling var henholdsvis 60 og 8 måneder i Glivec - og INF - armene fem år, efter at den sidste patient var rekrutteret.
Five years after the last patient had been recruited, the median duration of first-line treatment was 60 and 8 months in the Glivec and IFN arms, respectively.
Medianvarigheden af andenlinjebehandling med Glivec var 45 måneder.
The median duration of second-line treatment with Glivec was 45 months.
Overordnet var den gennemsnitlige daglige dosis 389 ± 75 mg hos patienter som fik Glivec som førstevalg.
Overall, in patients receiving first-line Glivec, the average daily dose delivered was 389 ± 71 mg.
Progression blev defineret som enhver af følgende hændelser: progression til accellereret fase eller blastkrise, død, tab af CHR eller MCyR, eller patienter der ikke opnår CHR eller øget leukocyttal på trods af relevant terapeutisk behandling.
Progression was defined as any of the following events: progression to accelerated phase or blast crisis, death, loss of CHR or MCyR, or in patients not achieving a CHR an increasing WBC despite
Responsdata fremgår af Tabel 3.
Response data are shown in Table 3.
Respons i undersøgelsen vedrørende nydiagnosticeret CML (60 måneders
Response in newly diagnosed CML Study (60-month data)
(Bedste respons) Hæmatologisk respons
(Best response rates) Haematological response
CHR rate n (%)
CHR rate n (%)
Cytogenetisk respons Major respons n (%)
Cytogenetic response Major response n (%)
490 (88, 6%) * 14
490 (88.6%)*
[95% CI] Komplet CyR n (%) Delvis CyR n (%)
[95% CI] Complete CyR n (%) Partial CyR n (%)
Molekulær respons Major respons ved 12 måneder (%)
Molecular response Major response at 12 months (%) Major response at 24 months (%) * p < 0.001, Fischer’ s exact test
Ikke relevant **
2%* NA**
Molekulær major responskriterier:
** insufficient data, only two patients available with samples Haematological response criteria (all responses to be confirmed after ≥ 4 weeks):
I den perifere blodreduktion på ≥3 logaritmer i antallet af Bcr - ABL- transkriptioner (målt ved real- time kvantitativ reverse transkriptase PCR assay) over for en standardiserede baseline.
Major molecular response criteria: in the peripheral blood reduction of ≥ 3 logarithms in the amount of Bcr-Abl transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardised baseline.
Frekvensen for fuldstændig hæmatologisk respons, cytogenetisk respons og fuldstændig cytogenetisk respons for førstevalgsbehandling blev estimeret ved brug af Kaplan- Meier- metoden, hvor patienter, der ikke responderede, blev sorteret fra ved datoen for sidste undersøgelse.
Rates of complete haematological response, major cytogenetic response and complete cytogenetic response on first-line treatment were estimated using the Kaplan-Meier approach, for which non- responses were censored at the date of last examination.
Ved brug af denne metode øgedes den estimerede kumulative responsfrekvens for førstevalgsbehandling med Glivec fra 12 måneders behandling til 60 måneders behandling som følgende:
Using this approach, the estimated cumulative response rates for first-line treatment with Glivec improved from 12 months of therapy to 60 months of therapy as follows:
CHR fra 96, 4% til 98, 4% og CCYR fra 69, 5% til 86, 7%).
CHR from 96.4% to 98.4% and CCyR from 69.5% to 86.7%, respectively.
Ved 5- års opfølgning var der 86 (15, 6%) progressionshændelser i Glivec- armen:
With 5 years follow-up, there were 86 (15.6%) progression events in the Glivec arm:
35 (6, 3%) omhandlede progression til accelereret fase/ blastkrise, 28 (5, 1%) tab af MCyR, 14 (2, 5%) tab af CHR eller stigning i WBC, og 9 (1, 6%) dødsfald ikke relateret til CML.
35 (6.3%) involving progression to accelerated phase/ blast crisis, 28 (5.1%) loss of MCyR, 14 (2.5%) loss of CHR or increase in WBC, and 9 (1.6%) CML unrelated deaths.
Til sammenligning ver der 155 (28, 0%) hændelser i IFN+Ara- C- armen af hvilke 128 opstod under førstevalgsbehandling med IFN+Ara- C.
In contrast, there were 155 (28.0%) events in the IFN+Ara-C arm, of which 128 occurred during first-line treatment with IFN+Ara-C.
Den estimerede frekvens af patienter fri for progressions til fremskreden fase eller blastkrise efter 60 måneder var signifikant højere i Glivec- armen end i IFN- armen (92, 9% versus 86, 2%, p < 0, 001).
The estimated rate of patients free of progression to accelerated phase or blast crisis at 60 months was significantly higher in the Glivec arm compared to the IFN arm (92.9% versus 86.2%, p < 0.001).
Den årlige frekvens for progression til fremskreden fase eller blastkrise aftog jo længere behandlingen stod på og var mindre end 1% årlig i fjerde og femte år.
The annual rate of progression to accelerated phase or blast crisis decreased with time on therapy and was less than 1% annually in the fourth and fifth years.
Den estimerede progressionsfri overlevelse efter 60 måneder var 83, 2% i Glivec- armen og 64, 1% i kontrolarmen (p < 0, 001).
The estimated rate of progression-free survival at 60 months was 83.2% in the Glivec arm and 64.1% in the control arm (p < 0.001).
I alt døde 57 (10, 3%) og 73 (13, 2) patienter i henholdsvis Glivec - og IFN+Ara- C- grupperne.
A total of 57 (10.3%) and 73 (13.2%) patients died in the Glivec and IFN+Ara-C groups, respectively.
Ved 60 måneder var den estimerede samlede overlevelse 89, 4% (86, 92) vs.
At 60 months the estimated overall survival is 89.4% (86, 92) vs.
85, 6% (82, 89) i henholdsvis de randomiserede Glivec - og IFN+Ara- C- grupper (p=0, 049, log- rank test).
85.6% (82, 89) in the randomised Glivec and the IFN+Ara-C groups, respectively (p=0.049, log-rank test).
Dette tid- til- hændelse effektmål er stærkt påvirket af det høje antal skift fra IFN+Ara- C- armen til Glivec- armen.
This time-to-event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to Glivec.
Effekten af Glivec- behandling på overlevelse i kronisk fase, nyligt diagnostiseret CML er blevet yderligere undersøgt i en retrospektiv analyse af ovenstående rapporterede Glivec- data med primærdata fra et andet fase III- studie hvor IFN+Ara- C (n=325) blev anvendt i et tilsvarende behandlingsregime.
The effect of Glivec treatment on survival in chronic phase, newly diagnosed CML has been further examined in a retrospective analysis of the above reported Glivec data with the primary data from another Phase III
I denne retrospektive analyse af total overlevelse blev Glivecs overlegenhed vist i forhold til IFN+Ara - C (p < 0, 001); inden for 42 måneder var 47 (8, 5%) Glivec- patienter og 63 (19, 4%) IFN+Ara- C - patienter døde.
In this retrospective analysis, the superiority of Glivec over IFN+Ara-C in overall survival was demonstrated (p < 0.001); within 42 months, 47 (8.5%) Glivec patients and 63 (19.4%) IFN+Ara-C patients had died.
Graden af cytogenisk respons og molekylært respons havde en klar effekt på langtidsudfaldet for patienter i Glivec- behandling.
The degree of cytogenetic response and molecular response had a clear effect on long-term outcomes in patients on Glivec.